Skip to main content
Contact Us
Subscribe
E-Edition
30°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
February 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
January 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
December 12, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
November 29, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
November 28, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
November 15, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
November 09, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in Jefferies London Healthcare Conference
November 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
October 05, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in Upcoming October Conferences
September 28, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
August 10, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
July 17, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
July 06, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in Upcoming June Conferences
May 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
May 22, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
May 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Participate in Upcoming May Investor Conferences
May 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 25, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
March 23, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
March 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
February 01, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Tickers
ATHA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.